Skeletal response to teriparatide in real-life setting: effects of age, baseline bone density and prior denosumab use.

IF 1.6 4区 医学 Q2 Medicine
Acta Clinica Belgica Pub Date : 2023-12-01 Epub Date: 2023-07-19 DOI:10.1080/17843286.2023.2238375
Valerie Konings, Michaël R Laurent, Sigrid Janssens, Jolan Dupont, Evelien Gielen, Marian Dejaeger
{"title":"Skeletal response to teriparatide in real-life setting: effects of age, baseline bone density and prior denosumab use.","authors":"Valerie Konings,&nbsp;Michaël R Laurent,&nbsp;Sigrid Janssens,&nbsp;Jolan Dupont,&nbsp;Evelien Gielen,&nbsp;Marian Dejaeger","doi":"10.1080/17843286.2023.2238375","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Teriparatide (TPD) is an osteoanabolic agent used in patients with high osteoporotic fracture risk. Predictors of therapeutic response to TPD in real-life setting are not well characterised. This study investigated the influence of previous antiresorptive therapy, age and other patient characteristics on the skeletal response to TPD.</p><p><strong>Methods: </strong>Retrospective study at the metabolic bone clinic, University Hospitals Leuven, Belgium. Patients with osteoporosis and a high fracture burden received TPD for 9-18 months. Bone mineral density (BMD) was measured at baseline, 9 and 18 months at lumbar spine (LS), femoral neck (FN) and total hip (TH).</p><p><strong>Results: </strong>BMD at LS increased at 9 months (change mean (standard error) 6.8 % (0.7) <i>p</i> < 0.001) and at 18 months (8.0 % (0.9) <i>p</i> < 0.001), while BMD at FN and TH did not change significantly. Non-response in BMD change at the LS was seen with prior denosumab use (odds ratio 0.21, 95% confidence interval (CI) 0.049-0.912, <i>p</i> = 0.037). Changes in BMD at TH were significantly greater in younger patients and in patients with a lower baseline BMD.</p><p><strong>Conclusion: </strong>TPD-induced changes in BMD at TH might depend on age and baseline BMD and at LS on prior denosumab use. The results suggest that these factors may be relevant for clinical decision making when initiating TPD treatment, although larger studies are needed to confirm these findings.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"446-451"},"PeriodicalIF":1.6000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Clinica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17843286.2023.2238375","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Teriparatide (TPD) is an osteoanabolic agent used in patients with high osteoporotic fracture risk. Predictors of therapeutic response to TPD in real-life setting are not well characterised. This study investigated the influence of previous antiresorptive therapy, age and other patient characteristics on the skeletal response to TPD.

Methods: Retrospective study at the metabolic bone clinic, University Hospitals Leuven, Belgium. Patients with osteoporosis and a high fracture burden received TPD for 9-18 months. Bone mineral density (BMD) was measured at baseline, 9 and 18 months at lumbar spine (LS), femoral neck (FN) and total hip (TH).

Results: BMD at LS increased at 9 months (change mean (standard error) 6.8 % (0.7) p < 0.001) and at 18 months (8.0 % (0.9) p < 0.001), while BMD at FN and TH did not change significantly. Non-response in BMD change at the LS was seen with prior denosumab use (odds ratio 0.21, 95% confidence interval (CI) 0.049-0.912, p = 0.037). Changes in BMD at TH were significantly greater in younger patients and in patients with a lower baseline BMD.

Conclusion: TPD-induced changes in BMD at TH might depend on age and baseline BMD and at LS on prior denosumab use. The results suggest that these factors may be relevant for clinical decision making when initiating TPD treatment, although larger studies are needed to confirm these findings.

现实生活中对特立帕肽的骨骼反应:年龄、基线骨密度和既往使用狄诺沙单抗的影响。
目的:特立帕肽(TPD)是一种用于骨质疏松性骨折高危患者的骨合成代谢剂。在现实生活中,TPD治疗反应的预测因素没有很好的特征。本研究调查了既往抗再吸收治疗、年龄和其他患者特征对TPD骨骼反应的影响。方法:在比利时鲁汶大学医院代谢骨诊所进行回顾性研究。骨质疏松症和高骨折负荷患者接受TPD治疗9-18 月。在基线、9和18时测量骨密度(BMD) 腰椎(LS)、股骨颈(FN)和全髋关节(TH)的月数。结果:LS的BMD在9时增加 月(变化平均值(标准误差)6.8%(0.7)p p p = 0.037)。年轻患者和基线BMD较低的患者在TH时的BMD变化明显更大。研究结果表明,在开始TPD治疗时,这些因素可能与临床决策有关,尽管还需要更大规模的研究来证实这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Clinica Belgica
Acta Clinica Belgica 医学-医学:内科
CiteScore
2.90
自引率
0.00%
发文量
44
审稿时长
6-12 weeks
期刊介绍: Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine primarily publishes papers on clinical medicine, clinical chemistry, pathology and molecular biology, provided they describe results which contribute to our understanding of clinical problems or describe new methods applicable to clinical investigation. Readership includes physicians, pathologists, pharmacists and physicians working in non-academic and academic hospitals, practicing internal medicine and its subspecialties.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信